BeOne Medicines FY2025 revenue $5.34B (+40% YoY); guides FY2026 $6.2-6.4B

BeOne Medicines Ltd.

2025-FY EPS reported $0.19 revenue$5,343,033,000

Total revenue $5.34B full year (+40% YoY); Q4 revenue $1.5B (+33% YoY).
GAAP net income $286.9M vs loss $644.8M prior year; diluted EPS $2.53 vs loss $6.12.
BRUKINSA global sales $3.9B (+49% YoY); Q4 sales $1.1B (+38%).
Non-GAAP diluted EPS $8.09; Adjusted income from operations $1.1B from $45M prior year.
FY2026 revenue guidance $6.2B-$6.4B; management cites pipeline strength and global leadership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.